Astellas Pharma Inc.
ALPMY · OTC
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Market Cap | $2,602,970,564 | $2,927,195,489 | $3,430,258,242 | $3,505,860,452 |
| - Cash | $188,372,000 | $335,687,000 | $376,840,000 | $315,986,000 |
| + Debt | $831,426,000 | $920,016,000 | $200,007,000 | $212,744,000 |
| Enterprise Value | $3,246,024,564 | $3,511,524,489 | $3,253,425,242 | $3,402,618,452 |
| Revenue | $1,912,323,000 | $1,603,672,000 | $1,518,619,000 | $1,296,163,000 |
| % Growth | 19.2% | 5.6% | 17.2% | – |
| Gross Profit | $1,563,117,000 | $1,311,187,000 | $1,191,830,000 | $1,014,871,000 |
| % Margin | 81.7% | 81.8% | 78.5% | 78.3% |
| EBITDA | $248,046,000 | $194,814,000 | $246,878,000 | $241,519,000 |
| % Margin | 13% | 12.1% | 16.3% | 18.6% |
| Net Income | $50,747,000 | $17,045,000 | $98,714,000 | $124,086,000 |
| % Margin | 2.7% | 1.1% | 6.5% | 9.6% |
| EPS Diluted | 28.24 | 9.47 | 54.09 | 67.05 |
| % Growth | 198.2% | -82.5% | -19.3% | – |
| Operating Cash Flow | $194,512,000 | $172,475,000 | $332,325,000 | $258,160,000 |
| Capital Expenditures | -$57,330,000 | -$82,497,000 | -$88,541,000 | -$76,448,000 |
| Free Cash Flow | $137,182,000 | $89,978,000 | $243,784,000 | $181,712,000 |